Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Australia ETF (EWA) vs Revvity Inc (RVTY) Price & Performance

iShares MSCI Australia ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Australia ETF vs Revvity Inc — how do they compare? iShares MSCI Australia ETF trades at $29.89, while Revvity Inc trades at $116.16 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals.

EWARVTY
Sector
Broad Market / FactorTechnology
52-Week High
$30.41$117.75
52-Week Low
$24.95$82.26
Market Cap
$12.91B
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Australia ETF

EWA trades at $29.985, down 0.22% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX readings. The stock shows neutral momentum oscillators, and support/resistance levels are consolidated around $30. A dividend of $0.40 is scheduled for June 2026, providing income potential.

Outlook remains cautiously optimistic given technical strength, but fundamental data is unavailable for valuation assessment. Risks include reliance on Australian economic conditions and sector-specific headwinds. Investors should seek updated financials for a complete view amid mixed sentiment.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Australia ETF

EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.

Read more on EWA

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY